Placebo + RO7204239
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Facioscapulohumeral Muscular Dystrophy (FSHD)
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Trial Timeline
Feb 7, 2023 → Oct 23, 2026
NCT ID
NCT05548556About Placebo + RO7204239
Placebo + RO7204239 is a phase 2 stage product being developed by Roche for Facioscapulohumeral Muscular Dystrophy (FSHD). The current trial status is active. This product is registered under clinical trial identifier NCT05548556. Target conditions include Facioscapulohumeral Muscular Dystrophy (FSHD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07137585 | Phase 1 | Recruiting |
| NCT05548556 | Phase 2 | Active |
Competing Products
12 competing products in Facioscapulohumeral Muscular Dystrophy (FSHD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACE-083 + ACE-083 or placebo | Merck | Phase 2 | 52 |
| ACE-083 | Merck | Phase 2 | 52 |
| AOC-1020 + Placebo | Avidity Biosciences | Phase 3 | 74 |
| Apitegromab + Placebo | Scholar Rock Holding | Phase 2 | 49 |
| Losmapimod oral tablet + Placebo oral tablet | Fulcrum Therapeutics | Phase 2 | 44 |
| Losmapimod + Placebo oral tablet | Fulcrum Therapeutics | Phase 3 | 69 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 44 |
| Losmapimod | Fulcrum Therapeutics | Phase 2 | 44 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| Placebo + ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |
| ATYR1940 | aTyr Pharma | Phase 1/2 | 33 |